Literature DB >> 24272871

Characterization of SLC26A9 in patients with CF-like lung disease.

Naziha Bakouh1, Thierry Bienvenu, Annick Thomas, Jordi Ehrenfeld, Huguette Liote, Delphine Roussel, Philippe Duquesnoy, Nicolette Farman, Marion Viel, Baya Cherif-Zahar, Serge Amselem, Rola Abou Taam, Aleksander Edelman, Gabrielle Planelles, Isabelle Sermet-Gaudelus.   

Abstract

Diffuse bronchiectasis is a common problem in respiratory clinics. We hypothesized that mutations in the solute carrier 26A9 (SLC26A9) gene, encoding for a chloride (Cl(-)) transporter mainly expressed in lungs, may lead to defects in mucociliary clearance. We describe two missense variants in the SLC26A9 gene in heterozygote patients presenting with diffuse idiopathic bronchiectasis : p.Arg575Trp, identified in a patient also heterozygote for p.Phe508del in the CFTR gene; and p.Val486Ile. Expression of both mutants in Xenopus laevis oocytes abolished SLC26A9-mediated Cl(-) conductance without decreasing protein membrane expression. Coexpression of CFTR with SLC26A9-p.Val486Ile resulted in a significant increase in the Cl(-) current induced by PKA stimulation, similar to that obtained in oocytes expressing CFTR and SLC26A9-WT. In contrast, coexpression of CFTR with SLC26A9-p.Arg575Trp inhibited SLC26A9-enhanced CFTR activation upon PKA. Further structure-function analyses led us to propose a site encompassing Arg575 in the SLC26A9-STAS domain for CFTR-SLC26A9 interaction. We hypothesize that SLC26A9-p.Arg575Trp prevented SLC26A9-mediated functional activation of CFTR by altering SLC26A9-CFTR interaction. Although we cannot confirm that these mutations by themselves are deleterious, we propose that they trigger the pathogenic role of a single CFTR mutation and provide insight into a novel mechanism of Cl(-) transport alteration across the respiratory mucosa, based on functional inhibition of CFTR.
© 2013 WILEY PERIODICALS, INC.

Entities:  

Keywords:  SLC26A9; Xenopus laevis oocytes; bronchiectasis; cystic fibrosis

Mesh:

Substances:

Year:  2013        PMID: 24272871     DOI: 10.1002/humu.22382

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  14 in total

1.  Bicarbonate transport of airway surface epithelia in luminally perfused mice bronchioles.

Authors:  Libin Liu; Akiko Yamamoto; Makoto Yamaguchi; Itsuka Taniguchi; Nao Nomura; Miyuki Nakakuki; Yuka Kozawa; Tomoya Fukuyasu; Mayuko Higuchi; Erina Niwa; Tsutomu Tamada; Hiroshi Ishiguro
Journal:  J Physiol Sci       Date:  2022-02-23       Impact factor: 2.781

2.  SLC26A9 is selected for endoplasmic reticulum associated degradation (ERAD) via Hsp70-dependent targeting of the soluble STAS domain.

Authors:  Patrick G Needham; Jennifer L Goeckeler-Fried; Casey Zhang; Zhihao Sun; Adam R Wetzel; Carol A Bertrand; Jeffrey L Brodsky
Journal:  Biochem J       Date:  2021-12-22       Impact factor: 3.857

3.  Structural insights into the gating mechanism of human SLC26A9 mediated by its C-terminal sequence.

Authors:  Ximin Chi; Xueqin Jin; Yun Chen; Xiaoli Lu; Xinyu Tu; Xiaorong Li; Yuanyuan Zhang; Jianlin Lei; Jing Huang; Zhuo Huang; Qiang Zhou; Xiaojing Pan
Journal:  Cell Discov       Date:  2020-08-10       Impact factor: 10.849

4.  Generation and functional characterization of epithelial cells with stable expression of SLC26A9 Cl- channels.

Authors:  Johanna J Salomon; Stephan Spahn; Xiaohui Wang; Joachim Füllekrug; Carol A Bertrand; Marcus A Mall
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-01-22       Impact factor: 5.464

5.  Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis.

Authors:  Anh-Thu N Lam; Melis A Aksit; Briana Vecchio-Pagan; Celeste A Shelton; Derek L Osorio; Arianna F Anzmann; Loyal A Goff; David C Whitcomb; Scott M Blackman; Garry R Cutting
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

6.  Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.

Authors:  Lisa J Strug; Tanja Gonska; Gengming He; Katherine Keenan; Wan Ip; Pierre-Yves Boëlle; Fan Lin; Naim Panjwani; Jiafen Gong; Weili Li; David Soave; Bowei Xiao; Elizabeth Tullis; Harvey Rabin; Michael D Parkins; April Price; Peter C Zuberbuhler; Harriet Corvol; Felix Ratjen; Lei Sun; Christine E Bear; Johanna M Rommens
Journal:  Hum Mol Genet       Date:  2016-10-15       Impact factor: 6.150

Review 7.  Physiological and Pathophysiological Relevance of the Anion Transporter Slc26a9 in Multiple Organs.

Authors:  Xuemei Liu; Taolang Li; Biguang Tuo
Journal:  Front Physiol       Date:  2018-08-28       Impact factor: 4.566

Review 8.  Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis.

Authors:  Anita Balázs; Marcus A Mall
Journal:  Front Pharmacol       Date:  2018-10-01       Impact factor: 5.810

9.  Loss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3(-) transport and reduces survival in CFTR-deficient mice.

Authors:  Xuemei Liu; Taolang Li; Brigitte Riederer; Henrike Lenzen; Lisa Ludolph; Sunil Yeruva; Biguang Tuo; Manoocher Soleimani; Ursula Seidler
Journal:  Pflugers Arch       Date:  2014-06-27       Impact factor: 3.657

Review 10.  Novel Roles for Chloride Channels, Exchangers, and Regulators in Chronic Inflammatory Airway Diseases.

Authors:  Monica Sala-Rabanal; Zeynep Yurtsever; Kayla N Berry; Tom J Brett
Journal:  Mediators Inflamm       Date:  2015-11-03       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.